Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Insights - The pharmaceutical sector has underperformed the overall market, with a significant decline in various sub-sectors, including a 6.88% drop in the biotechnology sector [1][32]. - Hidradenitis Suppurativa (HS) is identified as a chronic, recurrent inflammatory skin disease with a low prevalence in China and the U.S., highlighting the potential market for treatment options [2][10]. - The report emphasizes the increasing market share of new biologics targeting IL-17A and IL-17A/F, which are expected to outperform traditional therapies like Adalimumab [2][18]. Summary by Sections Market Performance - The overall A-share market declined by 4.32%, with the biotechnology sector falling by 6.88%, indicating a weaker performance compared to the broader market [1][32]. - Specific declines were noted in chemical pharmaceuticals (7.02%), biological products (7.46%), and medical services (6.90%) [1][32]. Hidradenitis Suppurativa Treatment Overview - HS affects approximately 0.03% of the population in China, with around 400,000 cases, and has been included in the rare disease directory [2][10]. - First-line treatments primarily involve antibiotics, while second-line therapies include biologics such as Adalimumab and newer agents targeting IL-17A and IL-17A/F [2][10]. Company Earnings Forecast and Investment Ratings - Key companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform," with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][42]. - The report highlights the strong growth potential in the CXO sector, particularly in CDMO and clinical CRO services, driven by new orders and emerging business lines [42][43]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already priced in various policy risks [42]. - It also emphasizes the importance of monitoring the clinical progress of innovative drugs in overseas markets, as this can significantly impact their commercialization potential [43][42]. Recommended Stocks - Mindray Medical is noted for its strong R&D and sales capabilities, benefiting from domestic healthcare infrastructure development [44]. - WuXi AppTec is recognized for its comprehensive service capabilities across the new drug development chain, poised to benefit from the global outsourcing market [44]. - Aier Eye Hospital is highlighted for its scale and commitment to introducing international standards in eye care [44].

来源：新浪基金∞工作室 11月27日，截止午间收盘，创业50ETF（159682）涨0.36%，报1.410元，成交额1.88亿元。创业50ETF （159682）重仓股方面，宁德时代截止午盘跌0.29%，中际旭创跌0.79%，东方财富涨0.21%，新易盛涨 5.53%，阳光电源涨1.27%，胜宏科技涨1.67%，汇川技术涨0.37%，迈瑞医疗涨2.01%，亿纬锂能涨 0.00%，同花顺跌0.34%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 创业50ETF（159682）业绩比较基准为创业板50指数收益率，管理人为景顺长城基金管理有限公司，基 金经理为汪洋、张晓南，成立（2022-12-23）以来回报为40.48%，近一个月回报为-4.24%。 ...

Company Overview - Mindray Medical is a leading company in the medical device industry, focusing on the research, manufacturing, marketing, and service of medical instruments [1][2] - The company was established on January 25, 1999, and went public on October 16, 2018 [1] Financial Performance - For the period from January to September 2025, Mindray Medical reported a revenue of 25.834 billion yuan, a year-on-year decrease of 12.38% [2] - The net profit attributable to the parent company for the same period was 7.570 billion yuan, down 28.83% year-on-year [2] - Since its A-share listing, the company has distributed a total of 35.336 billion yuan in dividends, with 25.025 billion yuan distributed over the past three years [3] Stock Performance - As of November 27, Mindray Medical's stock price increased by 2.02% to 197.31 yuan per share, with a total market capitalization of 239.227 billion yuan [1] - The stock has experienced a decline of 21.19% year-to-date, with a 0.77% drop over the last five trading days and an 8.37% decrease over the last 20 days [1] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 18.86% to 108,800, while the average number of circulating shares per person decreased by 15.87% to 11,139 shares [2] - The top ten circulating shareholders include significant institutional investors, with notable reductions in holdings among several ETFs [3]

Core Viewpoint - Despite a slowdown in the sector in the second half of the year, there remains strong interest from capital, with nearly 8 billion yuan of net inflow over five consecutive trading days, indicating a new round of investment layout [1] Group 1: Global Trends - Over the past decade, the number of pharmaceutical transactions globally has shown a steady growth trend, with multinational corporations (MNCs) needing to replenish their pipelines due to profit pressures [1] - By 2030, products with sales exceeding 5 billion USD that are nearing patent expiration will total nearly 200 billion USD, driving MNCs' enthusiasm for business development (BD) [1] Group 2: Chinese Pharmaceutical Companies - Chinese pharmaceutical companies are increasingly competitive globally, with the total amount of license-out transactions exceeding 100 billion USD this year, doubling compared to 2024 [2] - From 2015 to 2024, the number of original innovative drugs entering clinical trials from Chinese companies reached 4,382, surpassing the 4,009 from the United States, with 704 new drugs entering clinical trials in 2024, ranking first globally [2] - The number of innovative drugs developed by Chinese companies that have entered late-stage clinical trials is comparable to that of the United States [2] Group 3: Technological Trends - Antibody-drug conjugates (ADC) have become a hot topic for license-out transactions among Chinese companies over the past three years, transitioning from a follower to a leader in innovation [2] - Chinese companies are rapidly following innovations in immuno-oncology (IO) and have the potential to surpass competitors, with some products already authorized for international markets [2] Group 4: Policy Environment - The average price reduction of drugs in the 2025 medical insurance negotiations is expected to stabilize, with a significant proportion of newly added drugs being domestically produced [3] - Future centralized procurement may focus more on comprehensive value assessments rather than solely on low prices, emphasizing efficacy, quality, and patient accessibility [3] Group 5: Investment Opportunities - Focus on IO and ADC as foundational therapies for tumors, particularly with the upcoming expiration of PD-1 patents, which may lead to a market shift towards second-generation IO therapies [3] - Highlighted companies in the IO and ADC sectors include: 3SBio, Innovent Biologics, CanSino Biologics, Rongchang Biopharmaceuticals, Huahai Pharmaceutical, Yiming Pharmaceutical, Lepu Medical, Kelun-Biotech, and CSPC Pharmaceutical [3][5] - Emphasis on the internationalization of Chinese pharmaceutical companies, with a long-term view of the industry evolving into global leaders, particularly in innovative drugs and medical devices [3] - Notable companies in the medical device sector include Mindray Medical, United Imaging Healthcare, BGI Genomics, and Haitai New Light [3][5] - The CXO industry is expected to improve due to better supply-demand dynamics, with global investment recovery likely to boost client demand [4] - Key CXO leaders to watch include WuXi AppTec, WuXi Biologics, Kelun Pharmaceutical, Tigermed, and Jiuzhou Pharmaceutical [4][5]

Investment Rating - The report maintains a rating of "Accumulate" for the company [6][13]. Core Views - The company's domestic business is under short-term pressure, while the overseas market is experiencing rapid growth. The product line continues to expand, justifying the "Accumulate" rating [2][13]. Financial Summary - Total revenue for 2023 is projected at 4,444 million, with a slight increase to 4,471 million in 2024, followed by a decrease to 4,121 million in 2025, and then a recovery to 4,619 million in 2026 and 5,180 million in 2027 [4]. - Net profit attributable to the parent company is expected to be 1,217 million in 2023, decreasing to 1,194 million in 2024, and further down to 1,059 million in 2025, before rising to 1,224 million in 2026 and 1,409 million in 2027 [4]. - Earnings per share (EPS) is forecasted to be 2.13 in 2023, decreasing to 2.09 in 2024, and 1.85 in 2025, with a recovery to 2.14 in 2026 and 2.47 in 2027 [4][14]. Market Performance - The current stock price is 37.20, with a target price set at 44.94, indicating potential upside [6][7]. - The company has a total market capitalization of 21,257 million [7]. Business Outlook - The company is expected to see a stabilization in domestic business as industry policies are gradually implemented, and the process of import substitution accelerates [13]. - The overseas market is anticipated to grow rapidly due to ongoing product registrations and market expansion efforts [13]. - The product line has been enriched with 14 new products recently obtaining medical device registration, laying a foundation for future growth [13].

（文章来源：证券日报） 证券日报网讯迈瑞医疗11月26日在互动平台回答投资者提问时表示，截至2025年9月30日，公司股东总 数为108835户。 ...

Group 1 - Shenzhen Innovation Investment Group (深创投) plays a significant role in the success of various "star enterprises" such as DJI, Yushu, Moore Threads, SenseTime, and Mindray Medical [1] - Shenzhen's guiding fund has supported over 8,000 industrial projects and helped more than 1,800 companies become "specialized, refined, unique, and innovative" enterprises, with nearly 400 companies successfully listed [4][6] - The guiding fund, established in 2015 with a scale of 100 billion RMB, operates under a "government guidance + market operation" model, allowing professional fund management institutions to manage daily operations without government intervention [1][2] Group 2 - Since its inception, the Shenzhen guiding fund has mobilized nearly 500 billion RMB in capital through 13 government investment guiding funds, establishing over 300 sub-funds [2] - The guiding fund focuses on strategic emerging industries and future industry clusters, providing substantial capital support to key segments of the industrial chain and high-quality innovative projects [4][6] - The fund emphasizes collaboration with various stakeholders, including national and provincial funds, to enhance the effectiveness of fund utilization and resource allocation [6][12] Group 3 - The guiding fund's operational principles include "government guidance, market operation, collaborative synergy, risk prevention, and patient tolerance," ensuring a market-oriented and professional approach [5] - The fund has shifted its investment strategy to focus on specific industry clusters, establishing a "20+8" industrial fund group targeting 20 strategic emerging industries and 8 future industry clusters [6][11] - The fund aims to create a multi-dimensional capital ecosystem by linking fiscal funds with social and industrial capital, focusing on "bottleneck" areas and cutting-edge tracks [11][12] Group 4 - The guiding fund has implemented measures to stimulate investment in hard technology early-stage projects, including increasing venture capital supply and optimizing performance evaluation methods [7][8] - The selection criteria for fund managers emphasize experience in equity investment, sound risk control mechanisms, and the ability to provide industry-specific insights and resources [8][9] - Shenzhen aims to build a more internationally competitive venture capital center by innovating policies and constructing a collaborative ecosystem that integrates various funding sources and research institutions [10][11]

Core Viewpoint - The article highlights the selection of 57 high-end medical equipment promotion projects by the Ministry of Industry and Information Technology of China, with a focus on the inclusion of two domestic flow cytometer manufacturers, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Guilin Youlite Medical Electronics Co., Ltd. [2][3] Summary by Relevant Sections High-end Medical Equipment Promotion Projects - A total of 57 high-end medical equipment promotion projects have been selected, which include various advanced medical technologies such as photon counting detectors, superconducting magnetic resonance systems, and automated clinical laboratories [6][9]. - The projects aim to accelerate the clinical transformation and popularization of high-end medical equipment, enhancing the precision and intelligence of medical services in China [9]. Domestic Companies Involved - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. and Guilin Youlite Medical Electronics Co., Ltd. are the two domestic companies that have been selected for the flow cytometer promotion projects [2][3]. - The projects involve collaboration with over 200 medical institutions across various levels, including national medical centers and regional medical centers [9]. Project Coverage and Goals - The selected projects cover all 31 provinces and municipalities in China, aiming to promote the innovation and high-quality development of domestic medical equipment [9]. - The initiative is expected to enhance the clinical application of high-end medical equipment and support the upgrade of domestic medical technology [9].

Core Viewpoint - The article highlights the development of a high-end medical device industry cluster in Jiading, Shanghai, aiming to establish a competitive and influential biomedicine innovation hub in the Yangtze River Delta region [1] Group 1: Innovation Dimension - The goal is to achieve "double increments": over 100 new domestic Class III medical device registrations and more than 30 medical device products approved in overseas markets; the establishment of 2 to 3 high-quality innovation platforms such as technology innovation centers and specialized incubators [2] Group 2: Enterprise Dimension - The focus is on cultivating "double tiers": nurturing one internationally competitive leading enterprise, 2 to 3 champion enterprises in niche fields, and a number of specialized and innovative enterprises with core technologies and unique processes [2] Group 3: Industry Dimension - The target is to achieve "double breakthroughs": by 2027, the output value of the high-end medical device manufacturing industry is expected to reach 25 billion, with an industry scale of 50 billion, reflecting the full release of industrial cluster effects and the maturity of the industrial ecosystem [2] Group 4: Collaborative Innovation - Five collaborative innovation scenarios for medical devices were introduced, covering the entire chain from cutting-edge research and development to industrialization, which will effectively promote government-enterprise collaboration and functional integration [3]

Core Viewpoint - The medical device sector is experiencing slight fluctuations, with the medical device ETF reaching a historical high of 3.22 billion yuan, despite a minor decline of 0.11% [1] Industry Overview - The global IVD (in vitro diagnostics) market is maintaining steady growth, while the domestic market faces some pressure due to DRG/DIP policies. However, the demand for medical testing remains robust due to aging demographics [1] - The domestic biochemical diagnostics sector has largely overcome foreign dependencies, with the localization process nearly complete [1] Company Developments - The "Qiyuan Inspection Model," the first vertical large model focused on clinical testing in China, was officially launched at the Southern Inspection Medicine Academic Conference. This model was developed collaboratively by Mindray Medical and Southern Medical University Shenzhen Hospital, with support from multiple departments in Shenzhen [1] - The "Qiyuan" model differentiates itself from general large models by systematically building the reasoning and thinking capabilities of medical experts through a four-step process: professional learning, clinical training, thinking simulation, and continuous evolution [1] Market Performance - As of 14:24 on November 26, the medical device ETF (562600) showed a slight decline of 0.11%, with leading stocks including Haorunbo, Weili Medical, Lexin Medical, Dian Diagnostics, and Shuoshi Biology showing strong upward trends [1]